Glycan Testing for Gynecology and Menopause Clinics: Objectively Proving HRT Benefit

Glycan testing gives gynecology and menopause clinics an objective, blood-based way to measure whether HRT is actually working at a biological level, not just whether symptoms have improved. This approach analyzes IgG glycosylation, the sugar structures attached to antibodies that regulate inflammation, to calculate a patient's biological age and track how hormone therapy shifts it over time.

For practitioners building or expanding an HRT protocol, this article answers the practical questions around baselining, retest timing, and interpreting results in clinical practice. Clinics building a full HRT monitoring pathway can see the complete framework in GlycanAge for Healthcare Providers, Functional Medicine Clinics & Corporate Wellness Programs.

What does GlycanAge actually measure in menopause patients?

GlycanAge measures glycans, the sugar molecules attached to IgG antibodies, which reflect systemic inflammation and immune function, two of the central drivers of biological aging. Estrogen decline during menopause dysregulates IgG glycosylation, the process controlling which glycan structures attach to immune antibodies. This reduces anti-inflammatory glycans and increases pro-inflammatory ones. That shift can raise a patient's GlycanAge, their biological age as measured through glycans, by over a decade during the menopause transition. Because this decline reflects immune imbalance rather than estrogen deficiency alone, GlycanAge shows whether a treatment plan, whether estrogen-focused or broader, is restoring a more youthful glycan profile.

Why is glycan testing better suited to tracking HRT than repeated hormone panels?

Glycan testing gives an integrated measure of cumulative hormonal and metabolic influence, capturing long-term biological response rather than the day-to-day variability seen in blood hormone levels. Hormone panels answer "what is the level right now." GlycanAge answers "how has the immune system responded over time," which is the more clinically useful question when deciding whether a therapy is working. This distinction matters most during HRT titration, the process of adjusting dose and formulation, where clinicians need a stable signal to judge changes against rather than a fluctuating one.

"For the first time, we can prove the systemic benefits of HRT with objective data, and that changes the conversation from short-term relief to long-term health and longevity."

— Dr. Joseph Raffaele, MD, Founder, Raffaele Medical, New York City 

How much can HRT actually change a patient's GlycanAge?

Well-managed HRT protocols are associated with biological age reductions of 5 to 25 years in clinical testing, reflected in glycan shifts such as increased galactosylation, the addition of a sugar called galactose that is associated with anti-inflammatory activity. Not all HRT regimens produce the same glycan response. Formulation, route of administration, and dosage each influence hormonal balance and downstream glycan biology, meaning the same nominal prescription can produce different biological outcomes in different patients. GlycanAge gives the integrated measure that tells a clinician whether a given regimen is working at the molecular level, or whether dose adjustment, formulation change, or broader metabolic support is needed. One documented case: a 55-year-old woman four years post-menopause, already on oral estrogen-progesterone therapy but still experiencing poor sleep, joint aches, and vaginal dryness, showed an elevated GlycanAge relative to her chronological age. After switching to a bioidentical estradiol cream with gradual dose adjustments, her GlycanAge dropped by 10 years over 12 months, a shift not evident from symptoms alone but clear in her biological data.

When should a clinician run a baseline GlycanAge test before starting HRT?

A baseline GlycanAge test should be run before initiating HRT, giving the clinician a reference point against which to measure treatment response. Clinical assessment protocols recommend considering a baseline test in women aged 40 to 55 presenting with cycle irregularity, vasomotor symptoms such as hot flashes and night sweats, recurrent illness or poor injury healing, or sleep and mood disturbance. This applies even when GlycanAge is elevated relative to chronological age without other symptoms present. If a pre-menopausal GlycanAge result is available, it should be used as the individual's own benchmark going forward rather than a population average.

When should a patient retest GlycanAge after starting or adjusting HRT?

The optimal retest window is 3 to 4 months after initiating or adjusting an HRT regimen. This is long enough for glycan biology to reflect a genuine biological shift, and short enough to remain clinically actionable. Glycan profiles change in response to sustained hormonal and lifestyle conditions rather than daily fluctuations, so a result taken too soon after a change will not yet reflect the full biological response. At Raffaele Medical, a longevity clinic in New York City, GlycanAge testing has been incorporated into HRT management for hundreds of patients, using this baseline-and-retest structure to bridge the gap between symptom assessment and molecular outcomes. Set the retest date at the same time the protocol is set, so both patient and practitioner have a fixed point to evaluate response against.

What does it mean if a patient's GlycanAge doesn't improve on HRT?

A lack of improvement, or unexpected deterioration, in GlycanAge results signals the need for clinical review, not as a diagnosis but as an objective prompt to reassess the regimen. Unfavorable glycan profiles should be interpreted as markers of broader endocrine and immune imbalance, not simply estrogen deficiency. This may point to a need to address progesterone balance, androgen support, stress regulation, or metabolic health alongside hormone replacement.

"We want to know how quickly we can reverse this pro-inflammation. It's really crucial to our future health."

 — Dr. Louise Newson, Menopause Specialist, Founder of Newson Health

Repeated GlycanAge testing over time shows this trajectory clearly: a rise during a health disruption, followed by normalization as the patient responds to treatment and lifestyle change, with the biological age line tracking against the chronological age line. 

Can GlycanAge validate other hormone therapies beyond estrogen-based HRT?

Yes. GlycanAge is used in clinical practice to check whether hormone therapy, including HRT and thyroid replacement, is achieving genuine immune and metabolic benefit rather than just symptom relief. Because the underlying mechanism is IgG glycosylation responding to sustained hormonal and inflammatory conditions, the same baseline-and-retest logic applies across hormone optimization protocols generally, not only to estrogen-focused regimens. This gives clinicians a single, consistent biomarker across different treatment pathways rather than a separate monitoring approach for each hormone type.

How does GlycanAge fit alongside FSH and estradiol testing in a menopause pathway?

Menopause management built on FSH (follicle-stimulating hormone) and estradiol levels alone leaves the most important biology unmeasured. GlycanAge gives clinicians and patients an objective, validated measure of how hormonal change is reshaping inflammaging, the chronic low-grade inflammation that drives age-related decline, in midlife and beyond, and whether HRT is actually reversing it. Standard hormone panels confirm hormone levels; GlycanAge confirms whether those levels are translating into a genuine reduction in immune-driven biological aging. Used together, they give a complete picture: hormonal status alongside the systemic biological response to treatment.

Clinics building or expanding an HRT and menopause care pathway can integrate GlycanAge as a baseline-and-retest biomarker that turns patient conversations from symptom relief into measurable, evidence-based outcomes. Review a sample patient report to see how glycan indexes and disease-association data appear in practice, and explore how to build GlycanAge into your protocol.

Explore GlycanAge for Healthcare Providers →

External sources

• https://pmc.ncbi.nlm.nih.gov/articles/PMC7732334/ — Jurić J, Kohrt WM, Kifer D, Gavin KM, Pezer M, Nigrovic PA, Lauc G. Effects of estradiol on biological age measured using the glycan age index. Aging (Albany NY). 2020 Oct 13;12(19):19756-65. 

• https://pubmed.ncbi.nlm.nih.gov/28239652/ — Ercan A, Kohrt WM, Cui J, Deane KD, Pezer M, Yu EW, et al. Estrogens regulate glycosylation of IgG in women and men. JCI Insight. 2017 Feb 23;2(4):e89703.